MedPath

Cassava Sciences, Inc.

Cassava Sciences, Inc. logo
🇺🇸United States
Ownership
Public
Established
1998-01-01
Employees
29
Market Cap
-
Website
http://www.cassavasciences.com

Clinical Trials

9

Active:0
Completed:6

Trial Phases

3 Phases

Phase 1:3
Phase 2:3
Phase 3:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (33.3%)
Phase 2
3 (33.3%)
Phase 3
3 (33.3%)

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Phase 1
Completed
Conditions
Hepatic Insufficiency
Interventions
First Posted Date
2024-04-30
Last Posted Date
2025-01-07
Lead Sponsor
Cassava Sciences, Inc.
Target Recruit Count
27
Registration Number
NCT06390410
Locations
🇺🇸

Orange County Research Center, Lake Forest, California, United States

🇺🇸

Clinical Pharmacology of Miami, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Phase 1
Completed
Conditions
Absorption
Metabolism
Excretion
First Posted Date
2024-01-08
Last Posted Date
2025-03-20
Lead Sponsor
Cassava Sciences, Inc.
Target Recruit Count
8
Registration Number
NCT06195319
Locations
🇺🇸

Fortrea, Madison, Wisconsin, United States

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Phase 3
Terminated
Conditions
Alzheimer Disease
Interventions
First Posted Date
2022-10-12
Last Posted Date
2025-05-23
Lead Sponsor
Cassava Sciences, Inc.
Target Recruit Count
1081
Registration Number
NCT05575076
Locations
🇺🇸

MDFirst Research, Chandler, Arizona, United States

🇺🇸

CCT Research - Gilbert Neurology Partners, Gilbert, Arizona, United States

🇺🇸

Xenoscience, Inc., Phoenix, Arizona, United States

and more 128 locations

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Phase 2
Terminated
Conditions
Alzheimer's Disease
Interventions
First Posted Date
2022-04-29
Last Posted Date
2025-02-03
Lead Sponsor
Cassava Sciences, Inc.
Target Recruit Count
90
Registration Number
NCT05352763
Locations
🇺🇸

Cognitive Clinical Trials, Papillion, Nebraska, United States

🇺🇸

Valley Research Center, Inc., Imperial, California, United States

🇺🇸

Brain Matters Research, Delray Beach, Florida, United States

and more 7 locations

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Phase 3
Terminated
Conditions
Alzheimer Disease
Interventions
Drug: Placebo
First Posted Date
2021-08-30
Last Posted Date
2025-02-05
Lead Sponsor
Cassava Sciences, Inc.
Target Recruit Count
1125
Registration Number
NCT05026177
Locations
🇺🇸

Banner Alzheimer's Institute, Phoenix, Arizona, United States

🇺🇸

Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States

🇺🇸

Clinical Endpoints, Scottsdale, Arizona, United States

and more 84 locations
  • Prev
  • 1
  • 2
  • Next

News

Alzheimer's Disease Pipeline Shows Promise with 120+ Therapies in Development

• Over 120 Alzheimer's Disease treatment therapies are under development by 110+ companies globally, ranging from preclinical to marketed phases. • Emerging therapies like NRDN-201, ST-501, and KarXT are in various clinical trial phases, showing potential for significant market impact. • MapLight Therapeutics initiated a Phase 1 trial for ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis, with Phase 2 trials planned. • The FDA granted conventional approval to Leqembi (lecanemab-irmb), marking the first amyloid beta-directed antibody to transition from accelerated approval.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.